{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dimitrova M"],"funding":["Yale SPORE in Lung Cancer","NCI NIH HHS"],"pagination":["e1380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8388178"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(4)"],"pubmed_abstract":["<h4>Background</h4>In patients with advanced melanoma (MM), genomic profiling may guide treatment decisions in the frontline setting and beyond as specific tumor mutations can be treated with targeted therapy (TT). The range of panel sizes used to identify targetable mutations (TM) can range from a few dozen to whole exome sequencing (WES).<h4>Aim</h4>We investigated the impact of panel size and mutation status on first-line treatment selection and outcomes in MM.<h4>Methods and results</h4>We analyzed data for 1109 MM patients from three cohorts: 169 patients at NYULH and profiled with the 50 gene Ion Torrent panel (IT), 195 patients at MSKCC, profiled with the 400-gene MSK-IMPACT panel (MSK-I) and 745 patients at seven different sites profiled with WES. Data for cohorts 2 and 3 were extr"],"journal":["Cancer reports (Hoboken, N.J.)"],"pubmed_title":["Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database."],"pmcid":["PMC8388178"],"funding_grant_id":["P50 CA225450","P50 P50CA225450"],"pubmed_authors":["Jour G","Dimitrova M","Osman I","Kim MJ"],"additional_accession":[]},"is_claimable":false,"name":"Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database.","description":"<h4>Background</h4>In patients with advanced melanoma (MM), genomic profiling may guide treatment decisions in the frontline setting and beyond as specific tumor mutations can be treated with targeted therapy (TT). The range of panel sizes used to identify targetable mutations (TM) can range from a few dozen to whole exome sequencing (WES).<h4>Aim</h4>We investigated the impact of panel size and mutation status on first-line treatment selection and outcomes in MM.<h4>Methods and results</h4>We analyzed data for 1109 MM patients from three cohorts: 169 patients at NYULH and profiled with the 50 gene Ion Torrent panel (IT), 195 patients at MSKCC, profiled with the 400-gene MSK-IMPACT panel (MSK-I) and 745 patients at seven different sites profiled with WES. Data for cohorts 2 and 3 were extr","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-05-08T15:56:10.596Z","creation":"2022-02-11T10:05:29.106Z"},"accession":"S-EPMC8388178","cross_references":{"pubmed":["34109763"],"doi":["10.1002/cnr2.1380"]}}